GO:1990592 protein K69-linked ufmylation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990592 (protein K69-linked ufmylation) is a biological process in which a polymer of the ubiquitin-like protein UFM1 is formed through linkages between lysine 69 of UFM1 monomers and attached to a target protein.
• K69-linked ufmylation is a distinct poly-UFM1 chain type, analogous to polyubiquitin chains, and is emerging as a signaling modification in stress, autophagy, and immune regulation [1,2].
• Core enzymes include UBA5 (E1), UFC1 (E2), UFL1 (E3), and the UFM1-specific proteases UFSP1/UFSP2; DDRGK1 and CDK5RAP3 are key adaptors [1,3].
• K69-linked ufmylation regulates diverse substrates and pathways, including p53 stability, BECN1-dependent autophagy, ER-phagy via CYB5R3, and immune signaling through PD-1 and MAVS [2,3,4,5,6].
• Dysregulation of UFM1 system components is linked to cancer, neurodegeneration, and inflammatory/immune disorders, making K69-linked ufmylation a candidate therapeutic target [3,4,7,8].
• CRISPR knockout, point-mutation, knock-in, and overexpression models, combined with proteomics and functional assays, are essential to dissect K69-linked ufmylation biology [1,2,3].
Description
Protein K69-linked ufmylation (GO:1990592) is a post-translational modification in which the ubiquitin-like protein UFM1 is conjugated to target proteins as a polymer formed through isopeptide linkages between lysine 69 of UFM1 monomers. This process is part of the broader UFM1 system, which parallels ubiquitination but uses a dedicated enzymatic cascade and distinct biological outputs. Unlike monoufmylation, K69-linked poly-UFM1 chains can create multivalent interaction surfaces or alter substrate fate, and they are increasingly recognized as a signaling modality in cellular stress responses [1,2]. The UFM1 system is essential for embryonic development and cellular homeostasis, and its dysfunction is associated with a range of human pathologies. K69-linked ufmylation specifically has been implicated in the regulation of tumor suppressors, autophagy initiation, endoplasmic reticulum (ER) turnover, and immune cell activity [2,3,4,5,6]. For researchers, understanding GO:1990592 requires knowledge of the enzymatic machinery, the substrates modified, and the functional consequences of chain assembly. This article provides a research-grade overview of protein K69-linked ufmylation, covering its definition, mechanism, key genes, disease relevance, and experimental strategies. All statements are based on published literature cited by PMID, and the content is designed to support both human readers and generative-AI retrieval systems.
protein K69-linked ufmylation At A Glance
| GO ID | GO:1990592 |
|---|---|
| GO term | protein K69-linked ufmylation |
| Ontology | biological_process |
| Synonym | None |
| Definition | A protein ufmylation process in which a polymer of the ubiquitin-like protein UFM1 is formed by linkages between lysine residues at position 69 of the UFM1 monomers, is added to a protein. |
| Major function | Conjugation of K69-linked poly-UFM1 chains to target proteins, modulating their stability, interactions, or localization. |
| Related enzymes | UBA5 (E1), UFC1 (E2), UFL1 (E3), UFSP1/UFSP2 (proteases). |
| Key adaptors | DDRGK1, CDK5RAP3 [1,3]. |
| Example substrates | p53, BECN1, CYB5R3, PD-1, MAVS [2,3,4,5,6]. |
What Is GO:1990592?
Protein K69-linked ufmylation (GO:1990592) is a protein modification process in which a polymer of the ubiquitin-like protein UFM1 is synthesized via linkages between lysine 69 residues of UFM1 monomers and then attached to a target protein. In other words, it is the formation and conjugation of K69-linked poly-UFM1 chains onto substrate proteins, distinguishing it from monoufmylation or other chain types.
Why Is protein K69-linked ufmylation Important in Cell Biology?
Protein K69-linked ufmylation is important because it represents a distinct ubiquitin-like modification that regulates fundamental cellular processes such as protein stability, autophagy, ER homeostasis, and immune signaling [1,2,3,4,5,6]. Its dysregulation has been linked to cancer, neurodegeneration, and inflammatory diseases, and components of the UFM1 system are being explored as therapeutic targets [3,4,7,8]. Understanding K69-linked ufmylation at the molecular level can reveal new mechanisms of disease and guide the development of targeted interventions [1,8].
• Regulates tumor suppressor p53 stability by antagonizing ubiquitination, impacting cancer cell survival.
• Facilitates initiation of autophagy through stabilization of BECN1, linking ufmylation to cellular stress responses.
• Controls ER-phagy via ufmylation of CYB5R3, affecting ER turnover and quality control.
• Modulates immune responses by targeting PD-1 and MAVS, with implications for anti-tumor immunity and viral evasion [3,6].
• Is essential for embryonic development, as UFM1 system knockout is embryonic lethal in mice.
• Associated with neurodegenerative diseases, including tauopathies, where UFM1 system modifiers affect tau propagation.
• Potential target for cancer immunotherapy: targeting UFL1-PARP1 axis amplifies anti-tumor immunity.
• Provides a model for studying ubiquitin-like chain topology and signaling specificity.
• Enables research into crosstalk between ufmylation and other ubiquitin-like modifications.
• Offers opportunities for CRISPR-based functional genomics to identify novel components and substrates [1,3].
What Happens During protein K69-linked ufmylation?
Activation of UFM1 by the E1 enzyme UBA5
In simple terms: UFM1 is first turned on by an enzyme called UBA5, using energy from ATP.
The ufmylation cascade begins with the ATP-dependent activation of UFM1 by the E1 enzyme UBA5, which forms a thioester bond with UFM1. This step is analogous to ubiquitin activation and is required for all downstream ufmylation events, including K69-linked chain formation.
Transfer to the E2 enzyme UFC1
In simple terms: The activated UFM1 is passed to a second enzyme, UFC1.
Activated UFM1 is transferred from UBA5 to the E2 enzyme UFC1 via a transthioesterification reaction. UFC1 serves as the central carrier of UFM1 to the E3 ligase complex.
E3 ligase UFL1 and adaptors mediate substrate recognition
In simple terms: A third enzyme, UFL1, together with helper proteins, decides which target protein gets modified.
The E3 ligase UFL1, in complex with adaptor proteins such as DDRGK1 and CDK5RAP3, recognizes specific substrates and catalyzes the transfer of UFM1 to target lysine residues [1,3]. This step provides substrate specificity and is essential for K69-linked poly-UFM1 chain formation on substrates like p53 and BECN1 [2,4].
Formation of K69-linked poly-UFM1 chains
In simple terms: Multiple UFM1 molecules are linked together in a chain through lysine 69 before being attached to the target.
K69-linked ufmylation specifically involves the formation of UFM1 polymers where the linkage occurs between lysine 69 of one UFM1 monomer and the C-terminal glycine of the next. This chain assembly can occur on the substrate or on UFM1 itself, and the resulting poly-UFM1 chain alters the substrate's properties. The exact stoichiometry and regulation of chain length remain areas of active investigation.
Reversal by UFM1-specific proteases
In simple terms: Enzymes called UFSP1 and UFSP2 can remove UFM1 chains, making the modification reversible.
Deufmylation is carried out by UFM1-specific proteases, including UFSP1 and UFSP2, which cleave UFM1 from substrates and process UFM1 precursors. This reversibility allows dynamic regulation of K69-linked ufmylation in response to cellular signals.
Key Genes Involved in GO:1990592 protein K69-linked ufmylation
The following genes and proteins are central to the UFM1 system and K69-linked ufmylation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UFM1 | Ubiquitin-like protein that is conjugated to substrates; K69 is the linkage site for poly-UFM1 chains | Core modifier; mutations or knockdown alter all ufmylation processes |
| UBA5 | E1 activating enzyme for UFM1 | Essential for UFM1 activation; target for inhibiting ufmylation |
| UFC1 | E2 conjugating enzyme for UFM1 | Required for UFM1 transfer to E3; potential therapeutic target |
| UFL1 | E3 ligase that catalyzes UFM1 conjugation to substrates | Key specificity factor; knockout affects autophagy, immunity, and development [1,3,8] |
| DDRGK1 | Adaptor protein in UFL1 complex; stabilizes UFL1 | Mutations cause skeletal dysplasia; important for substrate recognition |
| CDK5RAP3 | Adaptor protein in UFL1 complex | Regulates UFM1 chain formation and substrate selection [1,3] |
| UFSP1 | UFM1-specific protease | Removes UFM1 from substrates; regulates UFM1 homeostasis |
| UFSP2 | UFM1-specific protease | Deufmylating enzyme; mutations linked to skeletal disorders |
| p53 | Tumor suppressor; substrate of K69-linked ufmylation | Ufmylation stabilizes p53 by antagonizing ubiquitination |
| BECN1 | Autophagy initiator; substrate of ufmylation | UFMylation stabilizes BECN1 to promote autophagy initiation |
| CYB5R3 | ER membrane protein; substrate of ufmylation | Ufmylation regulates ER-phagy through CYB5R3 |
| PD-1 | Immune checkpoint receptor; substrate of ufmylation | UFL1 ablation suppresses PD-1 ufmylation, enhancing anti-tumor immunity |
| MAVS | Mitochondrial antiviral signaling protein; substrate of ufmylation | UFMylation of MAVS affects NLRP3 inflammasome evasion by EBV |
| VCP/p97 | AAA+ ATPase; regulates UFMylation of BECN1 | VCP/p97 UFMylation stabilizes BECN1 and facilitates autophagy |
| PARP1 | DNA repair enzyme; interacts with UFL1 axis | Targeting UFL1-PARP1 axis amplifies anti-tumor immunity |
| TAU (MAPT) | Microtubule-associated protein; tauopathy modifier | UFM1 system modifiers affect tau propagation in iPSC models |
How Is protein K69-linked ufmylation Regulated?
K69-linked ufmylation is regulated at multiple levels. The enzymatic cascade is controlled by the availability and activity of UBA5, UFC1, UFL1, and adaptor proteins such as DDRGK1 and CDK5RAP3. Reversibility is provided by UFSP1 and UFSP2, which remove UFM1 from substrates. Cellular stress, including ER stress and DNA damage, can modulate ufmylation of specific substrates like p53 and BECN1 [2,4]. Additionally, crosstalk with ubiquitination and other ubiquitin-like modifications influences substrate fate. The UFL1-PARP1 axis has been implicated in immune regulation, suggesting that ufmylation is integrated with DNA damage responses.
protein K69-linked ufmylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| p53 | Cancer; tumor suppression | Cancer cell lines with p53 KO and UFM1 KO for ufmylation studies |
| BECN1 | Autophagy-related diseases; cancer | BECN1 KO and UFM1 KO cells to study autophagy initiation |
| CYB5R3 | ER-phagy; ER stress disorders | CYB5R3 KO and UFM1 KO cells for ER-phagy assays |
| PD-1 | Cancer immunotherapy | T cell-specific UFL1 KO mice for anti-tumor immunity |
| MAVS | Viral infection; inflammasome | MAVS KO cells and EBV infection models |
| MAPT (TAU) | Tauopathy; neurodegeneration | Human iPSC-derived neurons with UFM1 system mutations |
Cancer
K69-linked ufmylation is implicated in cancer through its regulation of p53 stability; ufmylation antagonizes p53 ubiquitination and maintains p53 levels, affecting tumor suppression. UFL1 ablation in T cells suppresses PD-1 ufmylation and enhances anti-tumor immunity, highlighting a role in immune evasion. Targeting the UFL1-PARP1 axis has been shown to amplify anti-tumor immunity, suggesting therapeutic potential.
Neurodegeneration
The UFM1 system has been linked to neurodegenerative diseases. In a human iPSC 4R tauopathy model, modifiers of tau propagation were identified, implicating ufmylation-related genes in tau pathology. This suggests that K69-linked ufmylation may influence protein aggregation and neuronal survival.
Inflammatory and immune disorders
UFMylation of MAVS by an Epstein-Barr virus protein allows evasion of the NLRP3 inflammasome, indicating a role in antiviral immunity and inflammation. Dysregulation of ufmylation may contribute to autoimmune or inflammatory conditions.
ER stress and metabolic disorders
Ufmylation of CYB5R3 regulates ER-phagy, a process important for ER quality control. Defects in this pathway could contribute to ER stress-related diseases, including metabolic and neurodegenerative disorders.
From protein K69-linked ufmylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the role of K69-linked ufmylation in p53 stability? | p53 KO and UFM1 KO cancer cell lines; point mutation of UFM1 K69 |
| How does ufmylation regulate autophagy initiation? | BECN1 KO and UFL1 KO cells; overexpression of K69-linked UFM1 |
| Does K69-linked ufmylation affect ER-phagy? | CYB5R3 KO and UFM1 KO cells; ER-phagy flux assays |
| What is the impact of ufmylation on anti-tumor immunity? | T cell-specific UFL1 KO mice; PD-1 ufmylation assays |
| How does ufmylation modulate tau propagation? | Human iPSC-derived neurons with UFM1 system KO or point mutations |
| What is the role of UFL1-PARP1 axis in immunity? | UFL1 KO and PARP1 KO tumor models; immune cell co-cultures |
How to Study the protein K69-linked ufmylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Identification of ufmylated proteins and chain topology | Mapping K69-linked UFM1 substrates |
| Western blot with UFM1 antibody | Levels of ufmylated proteins | Validating ufmylation of p53, BECN1 [2,4] |
| LC3 flux assay | Autophagic flux | Assessing autophagy initiation upon ufmylation changes |
| ER-phagy reporter | ER turnover | Studying CYB5R3 ufmylation effects |
| T cell activation assay | Immune cell function | Evaluating PD-1 ufmylation in anti-tumor immunity |
| CRISPR knockout screening | Gene function in ufmylation | Identifying novel regulators of K69-linked ufmylation |
| iPSC-derived neurons | Tau propagation | Modeling neurodegeneration linked to ufmylation |
| Tumor growth assay | In vivo anti-tumor immunity | Testing UFL1-PARP1 axis targeting |
Proteomic identification of ufmylated substrates
Mass spectrometry-based proteomics can identify proteins modified by K69-linked poly-UFM1 chains. Using UFM1-specific antibodies or tagged UFM1, researchers can enrich ufmylated proteins and map modification sites. This approach has revealed substrates such as p53, BECN1, and CYB5R3 [2,4,5].
Functional assays for autophagy and ER-phagy
Autophagy and ER-phagy can be monitored using LC3 flux assays, electron microscopy, and fluorescent reporters. Knockout of UFM1 system components or expression of K69-linked UFM1 mutants can reveal effects on autophagosome formation and ER turnover [2,5].
Immune cell functional assays
To study ufmylation in immunity, researchers use T cell activation assays, cytokine profiling, and tumor killing assays. UFL1 ablation in T cells enhances anti-tumor immunity, which can be measured by PD-1 ufmylation status and tumor growth in mouse models [3,8].
CRISPR screening for ufmylation regulators
Genome-wide CRISPR knockout or activation screens can identify genes that modulate K69-linked ufmylation. Reporters of UFM1 conjugation or substrate stability can be used to isolate regulators, as demonstrated in studies of the UFM1 system [1,3].
How CRISPR Can Be Used to Study GO:1990592 protein K69-linked ufmylation
Knockout
CRISPR knockout of UFM1 system genes (e.g., UBA5, UFC1, UFL1, DDRGK1) can abolish K69-linked ufmylation, enabling studies of its loss-of-function phenotypes in cancer, autophagy, and immunity [1,3]. Knockout of substrate genes like p53 or BECN1 helps dissect specific pathways [2,4].
Point Mutation
Point mutation of UFM1 at lysine 69 (K69R) prevents K69-linked chain formation, allowing researchers to distinguish K69-linked ufmylation from monoufmylation or other chain types. Such mutants are valuable for mechanistic studies.
Knock-in
Knock-in of tagged UFM1 (e.g., HA or FLAG) or substrate mutants enables affinity purification and imaging of ufmylated proteins in native contexts. Knock-in of disease-associated mutations in UFM1 system genes can model human disorders.
Overexpression
Overexpression of UFM1, UFL1, or substrate proteins can enhance K69-linked ufmylation and reveal gain-of-function phenotypes, such as increased autophagy or altered immune signaling [2,3,4]. Inducible systems allow temporal control.
How EDITGENE Supports protein K69-linked ufmylation Research
Researchers studying protein K69-linked ufmylation-related genes often need to determine whether a candidate gene is causally involved in the modification, how it affects substrate fate, and whether it can be targeted therapeutically. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for protein K69-linked ufmylation research.
Frequently Asked Questions About protein K69-linked ufmylation
What is protein K69-linked ufmylation?
Protein K69-linked ufmylation (GO:1990592) is a process where a polymer of the ubiquitin-like protein UFM1 is formed through linkages between lysine 69 of UFM1 monomers and attached to a target protein.
What genes are involved in protein K69-linked ufmylation?
Key genes include UFM1, UBA5, UFC1, UFL1, DDRGK1, CDK5RAP3, UFSP1, and UFSP2, as well as substrates like p53, BECN1, and CYB5R3 [1,2,4,5].
How is K69-linked ufmylation different from ubiquitination?
It uses UFM1 instead of ubiquitin and a distinct enzymatic cascade (UBA5, UFC1, UFL1), and the chain linkage is through UFM1 lysine 69.
What diseases are associated with K69-linked ufmylation?
It has been linked to cancer, neurodegeneration, inflammatory disorders, and ER stress-related diseases [3,4,5,6,7,8].
What is the role of UFL1 in K69-linked ufmylation?
UFL1 is the E3 ligase that catalyzes the transfer of UFM1 to substrates, often in complex with DDRGK1 and CDK5RAP3, and is essential for K69-linked chain formation [1,3].
How can I study K69-linked ufmylation in the lab?
Common methods include mass spectrometry, western blot with UFM1 antibodies, autophagy flux assays, and CRISPR knockout/knock-in models [1,2,5].
Is K69-linked ufmylation reversible?
Yes, UFSP1 and UFSP2 are proteases that remove UFM1 from substrates, making the modification dynamic.
What is the significance of UFM1 K69 in chain formation?
Lysine 69 is the specific residue on UFM1 that forms the isopeptide bond in poly-UFM1 chains; mutating it to arginine (K69R) prevents K69-linked chain formation.
Can K69-linked ufmylation be targeted for cancer therapy?
Targeting the UFL1-PARP1 axis has been shown to amplify anti-tumor immunity, suggesting therapeutic potential.
What model systems are used to study K69-linked ufmylation?
Cell lines with CRISPR knockouts, point mutations, knock-ins, and overexpression, as well as mouse models and iPSC-derived neurons, are commonly used [1,3,7].
Conclusion
Protein K69-linked ufmylation (GO:1990592) is a specialized ubiquitin-like modification that regulates critical cellular processes, including protein stability, autophagy, ER homeostasis, and immunity [1,2,3,4,5,6]. Its dysregulation is implicated in cancer, neurodegeneration, and inflammatory diseases, making it an attractive target for therapeutic intervention [3,4,7,8]. Continued research using CRISPR-based models and advanced proteomics will further elucidate its mechanisms and translational potential.
References
- 1. Zhou X et al.. 2024. UFMylation: a ubiquitin-like modification.. Trends Biochem Sci 49(1):52-67 PMID: 37945409
- 2. Wang Z et al.. 2024. VCP/p97 UFMylation stabilizes BECN1 and facilitates the initiation of autophagy.. Autophagy 20(9):2041-2054 PMID: 38762759
- 3. He C et al.. 2024. UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity.. Mol Cell 84(6):1120-1138.e8 PMID: 38377992
- 4. Liu J et al.. 2020. UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination.. Nat Cell Biol 22(9):1056-1063 PMID: 32807901
- 5. Ishimura R et al.. 2022. The UFM1 system regulates ER-phagy through the ufmylation of CYB5R3.. Nat Commun 13(1):7857 PMID: 36543799
- 6. Yiu SPT et al.. 2023. An Epstein-Barr virus protein interaction map reveals NLRP3 inflammasome evasion via MAVS UFMylation.. Mol Cell 83(13):2367-2386.e15 PMID: 37311461
- 7. Parra Bravo C et al.. 2024. Human iPSC 4R tauopathy model uncovers modifiers of tau propagation.. Cell 187(10):2446-2464.e22 PMID: 38582079
- 8. Song W et al.. 2025. Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity.. Cell Rep 44(10):116433 PMID: 41105513
